CRISPR-Cas9 screen identifies oxidative phosphorylation as essential for cancer cell survival at low extracellular pH
Johanna Michl,
Yunyi Wang,
Stefania Monterisi,
Wiktoria Blaszczak,
Ryan Beveridge,
Esther M. Bridges,
Jana Koth,
Walter F. Bodmer,
Pawel Swietach
Affiliations
Johanna Michl
Department of Physiology, Anatomy and Genetics, Parks Road, Oxford OX1 3PT, UK; Corresponding author
Yunyi Wang
Department of Physiology, Anatomy and Genetics, Parks Road, Oxford OX1 3PT, UK
Stefania Monterisi
Department of Physiology, Anatomy and Genetics, Parks Road, Oxford OX1 3PT, UK
Wiktoria Blaszczak
Department of Physiology, Anatomy and Genetics, Parks Road, Oxford OX1 3PT, UK
Ryan Beveridge
Virus Screening Facility, MRC Weatherall Institute for Molecular Medicine, John Radcliffe Hospital, Oxford OX3 9DS, UK
Esther M. Bridges
Department of NDM Experimental Medicine, MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, JR Hospital, Headington, Oxford OX3 9DS, UK
Jana Koth
MRC Weatherall Institute for Molecular Medicine, John Radcliffe Hospital, Headington, Oxford OX3 9DS, UK
Walter F. Bodmer
MRC Weatherall Institute for Molecular Medicine, John Radcliffe Hospital, Headington, Oxford OX3 9DS, UK
Pawel Swietach
Department of Physiology, Anatomy and Genetics, Parks Road, Oxford OX1 3PT, UK; Corresponding author
Summary: Unlike most cell types, many cancer cells survive at low extracellular pH (pHe), a chemical signature of tumors. Genes that facilitate survival under acid stress are therefore potential targets for cancer therapies. We performed a genome-wide CRISPR-Cas9 cell viability screen at physiological and acidic conditions to systematically identify gene knockouts associated with pH-related fitness defects in colorectal cancer cells. Knockouts of genes involved in oxidative phosphorylation (NDUFS1) and iron-sulfur cluster biogenesis (IBA57, NFU1) grew well at physiological pHe, but underwent profound cell death under acidic conditions. We identified several small-molecule inhibitors of mitochondrial metabolism that can kill cancer cells at low pHe only. Xenografts established from NDUFS1−/− cells grew considerably slower than their wild-type controls, but growth could be stimulated with systemic bicarbonate therapy that lessens the tumoral acid stress. These findings raise the possibility of therapeutically targeting mitochondrial metabolism in combination with acid stress as a cancer treatment option.